Article

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML

2025-08-21

Abstract excerpt

Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) with high-risk features including TP53 mutations and deletions have poor outcomes due to lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine receptor-like 2 (CCRL2) is overexpressed in MDS and secondary AML (sAML) compared to healthy hematopoietic cells and we recently found that TP53 -mutated MDS/AML a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9eec2c11-d569-5138-b6dc-dbbc8105bb28
DOI: 10.1101/2025.08.17.670714

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLDOI 10.1101/2025.08.17.670714Read

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.Semantic proximity Read

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemiaSemantic proximity Read

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidineSemantic proximity Read

SRRM2 is a target for the immunotherapy of AML with rationally designed CAR-T cellsSemantic proximity Read

CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.Semantic proximity Read

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsSemantic proximity Read

Positive impact of high-throughput drug sensitivity assay and salvage autologous CD19 CAR-T therapy on second marrow relapse of acute lymphoblastic leukemia with NT5C2 mutationSemantic proximity Read

CXCR2 As a Novel Target for Overcoming Resistance to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia CellsSemantic proximity Read

Multi-omics analysis reveals CLEC2A is a leukemia-restricted CART target in KMT2A-rearranged Acute Myeloid LeukemiaSemantic proximity Read

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Semantic proximity Read

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read